Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Long-term safety of subcutaneous abatacept in rheumatoid arthritis: integrated analysis of clinical trial data representing more than four years of treatment.

Alten R, Kaine J, Keystone E, Nash P, Delaet I, Genovese MC.

Arthritis Rheumatol. 2014 Aug;66(8):1987-97. doi: 10.1002/art.38687.

2.

Subcutaneous abatacept for the treatment of rheumatoid arthritis: longterm data from the ACQUIRE trial.

Genovese MC, Tena CP, Covarrubias A, Leon G, Mysler E, Keiserman M, Valente R, Nash P, Simon-Campos JA, Box J, Legerton CW 3rd, Nasonov E, Durez P, Delaet I, Teng J, Alten R.

J Rheumatol. 2014 Apr;41(4):629-39. doi: 10.3899/jrheum.130112. Epub 2014 Mar 1.

3.

Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program.

Weinblatt ME, Moreland LW, Westhovens R, Cohen RB, Kelly SM, Khan N, Pappu R, Delaet I, Luo A, Gujrathi S, Hochberg MC.

J Rheumatol. 2013 Jun;40(6):787-97. doi: 10.3899/jrheum.120906. Epub 2013 Apr 15.

4.

Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label study.

Nash P, Nayiager S, Genovese MC, Kivitz AJ, Oelke K, Ludivico C, Palmer W, Rodriguez C, Delaet I, Elegbe A, Corbo M.

Arthritis Care Res (Hoboken). 2013 May;65(5):718-28. doi: 10.1002/acr.21876.

5.

Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study.

Keystone EC, Kremer JM, Russell A, Box J, Abud-Mendoza C, Elizondo MG, Luo A, Aranda R, Delaet I, Swanink R, Gujrathi S, Luggen M.

Ann Rheum Dis. 2012 Jun;71(6):857-61. doi: 10.1136/annrheumdis-2011-200355. Epub 2012 Feb 2.

PMID:
22302417
6.

Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase Iiib ALLOW study).

Kaine J, Gladstein G, Strusberg I, Robles M, Louw I, Gujrathi S, Pappu R, Delaet I, Pans M, Ludivico C.

Ann Rheum Dis. 2012 Jan;71(1):38-44. doi: 10.1136/annrheumdis-2011-200344. Epub 2011 Sep 13.

7.

Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate.

Genovese MC, Covarrubias A, Leon G, Mysler E, Keiserman M, Valente R, Nash P, Simon-Campos JA, Porawska W, Box J, Legerton C 3rd, Nasonov E, Durez P, Aranda R, Pappu R, Delaet I, Teng J, Alten R.

Arthritis Rheum. 2011 Oct;63(10):2854-64. doi: 10.1002/art.30463.

8.

Antibody neutralization of picornaviruses: can fever help?

Boeyé A, Delaet I, Brioen P.

Trends Microbiol. 1994 Jul;2(7):255-7. Review.

PMID:
8081653
9.

Capsid destabilization is required for antibody-mediated disruption of poliovirus.

Delaet I, Boeyé A.

J Gen Virol. 1994 Mar;75 ( Pt 3):581-7.

PMID:
8126454
10.
11.

Antigenic N to H conversion of poliovirus by a monoclonal antibody at low ionic strength.

Delaet I, Vrijsen R, Boeyé A.

Virology. 1992 May;188(1):93-101.

PMID:
1314469

Supplemental Content

Loading ...
Support Center